EarlyTox Cardiotoxicity Kit by Molecular Devices®
Manufacturer Molecular Devices®
Cell-based assays screen more compounds and identify toxicity earlier in drug discovery.
EarlyTox Cardiotoxicity Kit
For researchers looking to identify cardiotoxic compounds, the EarlyTox™ Cardiotoxicity Kit allows you to screen more compounds earlier in drug discovery.
Now you can prioritize leads and direct medicinal chemistry efforts sooner, improving productivity and reducing costs associated with extensive safety testing downstream.
The EarlyTox Cardiotoxicity Kit provides a fast, simple, and reliable fluorescence-based method for identifying cardiotoxic compounds in a biorelevant assay using stem-cell derived cardiomyocytes.
EarlyTox Cardiotoxicity Kit Features & Benefits:
- Eliminate cardiotoxic compounds and identify potential drug candidates
- Measure 384 samples in minutes rather than hours
- Minimize non-specific effect of dye on beat characteristics
- Reduce well-to-well variation and improve data quality
- Largest signal dynamic range available
- Benchmark against three reference compounds: isoproterenol, sotalol and propranolol
Product Overview
